Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.

Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G

Bone19 Oct 2018Cited by 26 (Europe PMC)

PMID30343166DOI10.1016/j.bone.2018.10.012PepBankPUB-30343166

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, both abaloparatide groups gained more tibial cortical thickness than vehicle controls.
In plain wordsIn rats with removed testes, both abaloparatide groups gained more tibial cortical thickness than vehicle controls.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial cortical thickness
Study
ratn = 30
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
pQCT also indicated greater gains in tibial cortical thickness in both abaloparatide groups versus vehicle controls.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316603
02AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, one or both abaloparatide groups gained more areal BMD at all analyzed sites than vehicle controls.
In plain wordsIn rats with removed testes, one or both abaloparatide groups gained more areal bone density than vehicle controls.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseAreal BMD
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
DXA and pQCT showed that one or both abaloparatide groups gained more areal and volumetric BMD at all sites analyzed compared with vehicle controls, leading to substantial or complete reversal of ORX-induced BMD deficits.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316601
03AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, one or both abaloparatide groups gained more volumetric BMD at all analyzed sites than vehicle controls.
In plain wordsIn rats with removed testes, one or both abaloparatide groups gained more volumetric bone density than vehicle controls.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseVolumetric BMD
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
DXA and pQCT showed that one or both abaloparatide groups gained more areal and volumetric BMD at all sites analyzed compared with vehicle controls, leading to substantial or complete reversal of ORX-induced BMD deficits.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316602
04AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, abaloparatide increased trabecular bone formation compared with vehicle.
In plain wordsIn rats with removed testes, abaloparatide increased trabecular bone formation compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular bone formation
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Tibial bone histomorphometry showed greater trabecular bone formation and bone volume and improved micro-architecture with abaloparatide, with no increase in osteoclasts.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316604
05AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, abaloparatide increased trabecular bone volume compared with vehicle.
In plain wordsIn rats with removed testes, abaloparatide increased trabecular bone volume compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular bone volume
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Tibial bone histomorphometry showed greater trabecular bone formation and bone volume and improved micro-architecture with abaloparatide, with no increase in osteoclasts.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316605
06AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, abaloparatide improved trabecular microarchitecture compared with vehicle.
In plain wordsIn rats with removed testes, abaloparatide improved trabecular bone structure compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTrabecular microarchitecture
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Tibial bone histomorphometry showed greater trabecular bone formation and bone volume and improved micro-architecture with abaloparatide, with no increase in osteoclasts.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316606
07AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, abaloparatide did not increase osteoclasts compared with vehicle.
In plain wordsIn rats with removed testes, abaloparatide did not increase bone-resorbing cells compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeOsteoclasts
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Tibial bone histomorphometry showed greater trabecular bone formation and bone volume and improved micro-architecture with abaloparatide, with no increase in osteoclasts.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316607
08AnimalAnimal study (in vivo)Efficacy outcome
In orchiectomized rats, abaloparatide improved the balance of bone formation versus resorption markers, which correlated with BMD changes.
In plain wordsIn rats with removed testes, abaloparatide improved the balance of bone formation versus resorption markers compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableBone formation-resorption marker balance
Study
ratn: not reported in source
Orchiectomized rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 25 μg/kg/d · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Abaloparatide also led to significant improvements in the balance of biochemical bone formation markers versus bone resorption markers, which correlated with BMD changes.
2 context sentences(design, population, supporting numbers)
Summary · context
The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis.
Summary · context
ORX rats (n = 10/group) were then injected daily (s.c.) for 8 weeks with vehicle or abaloparatide at 5 (ABL5) or 25 μg/kg/d (ABL25).
Report a problemFND-3034316608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords